Our Pipeline
| Antigen class |
HLA type(s) | Indication | Discovery | Candidate Selection | Preclinical / Scale-up |
Clinical | |
|---|---|---|---|---|---|---|---|
| Cell Therapy Program 1 |
Tumor Associated Antigen |
HLA-A*02:01 or Non-A2 library |
Solid Tumors |
||||
| Cell Therapy Program 2 |
Novel | HLA-A*02:01 or Non-A2 library |
Solid Tumors |
ImmunoScape is building a diverse pipeline of novel TCR-based therapeutics against solid tumors. Our autologous cell therapy programs are directed towards a broad range of shared tumor targets and HLA alleles. Our HLA library consists of highly prevalent HLA alleles (HLA-A*01:01, HLA-A*02:01, HLA-A*03:01, HLA-A*11:01, HLA-A*24:02, HLA-B*07:02) and addresses a large part of the population from North America, Europe and South East Asia. Novel antigen classes include frameshifts, HERVs, indels, neojunctions, and other novel classes of shared antigens.
ImmunoScape’s rapidly evolving TCR portfolio encompasses wholly owned programs and opportunities for external partnering across different types of solid tumors and therapeutic modalities.